Poland· PL-100127157
Ceprotin
A protein c product containing proteinum humanum c, registered in Poland by Takeda Manufacturing Austria AG. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Protein c is registered in 9 of 19 countries.
Countries holding a registration under ATC B01AD12 (protein c), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Protein c · ATC B01AD12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Proteinum humanum C
- Manufacturer
- Takeda Manufacturing Austria AG
- Country
- Poland (PL)
- ATC code
- B01AD12
- ATC class
- Protein C
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990008254
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
34 interactions on record for protein c.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Protein c · interactions on record
34 records
- 1 severe
- 33 moderate
Most severe, free to view
- CaplacizumabB01AX07severe
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- HeparinB01AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Protein c in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceCEPROTIN 1000 UI/10 ml, poudre et solvant pour solution injectableTAKEDA MANUFACTURING AUSTRIA (AUTRICHE)
- BelgiumCeprotin 1000 IUTakeda Manufacturing Austria
- CzechiaCEPROTINTakeda Manufacturing Austria AG, Vídeň
- FinlandCeprotinBaxter AG
- United KingdomCeprotin 1000unit powder and solvent for solution for injection vialsTakeda UK Ltd
- IrelandCeprotinBaxter Vaccine AG
- IcelandCeprotinBaxter AG*
- SwedenCeprotin 1000 IE Pulver och vätska till injektionsvätska, lösningTakeda Manufacturing Austria AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- France · Protexel
- Iceland · Ceprotin
- Liechtenstein · Ceprotin
- Norway · Ceprotin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe61146d-2d8c-4283-8522-a34d7a75fcd8 GET /v1/drugs/fe61146d-2d8c-4283-8522-a34d7a75fcd8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "500 j.m.",
"packaging": "05909990008254 ¦ Rpz ¦ EU/1/01/190/001 ¦ 24221\n1 fiol. 500 j.m. proszku ¦ 1 fiol. 5 ml rozp. ¦ 1 igła z filtrem ¦ 1 igła dwustronna",
"substance": null,
"common_name": "Proteinum humanum C",
"pl_product_id": "100127157",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about protein c.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.